Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial.

ABSTRACT:

Introduction

As of November 2021, COVID-19 has killed more than 5 million people globally, including over 750 000 in the USA. Apart from corticosteroids, most available therapeutic options are at best marginally efficient in reducing disease severity and are extremely expensive. The systematic investigation of clinically approved drugs is a priority to determine what does mitigate disease severity. Oestradiol (E2) and progesterone (P4) produce a state of anti-inflammatory immune responses and immune tolerance, and enhanced antibody production. The goal of this trial is to evaluate the efficacy of a short E2 and P4 therapy, in addition to standard of care (SOC), in mitigating disease severity in COVID-19 hospitalised patients.

Methods and analysis

Phase 2, randomised, double

SUBMITTER: Lovre D 

PROVIDER: S-EPMC8635865 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature